Program
Hpk1 Inhibitor PRJ1-3024
Its studies are mostly in Melanoma, led by Zhuhai Yufan Biotechnologies.
Furthest: phase 2, since Mar 29, 20223 company-led studies, 3 open or runningNext primary completion: May 15, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zhuhai Yufan Biotechnologies | 33 open or running | phase 2since Mar 29, 2022 | Dec 7, 2021 | May 15, 2027phase 2 · NCT05315167 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 7, 2021First study: phase 1 study in Hereditary Sensory and Autonomic NeuropathiesFirst studyNCT05159700 · 39 enrolled · United States
- Mar 29, 2022Phase 2 study in Hereditary Sensory and Autonomic NeuropathiesNCT05315167 · 267 planned · China
- Dec 4, 2024Phase 2 study in MelanomaNCT06727630 · 40 planned · China
Ahead
- May 15, 2027Primary completion: phase 2 study in Hereditary Sensory and Autonomic NeuropathiesNCT05315167
TargetBeta
MAP4K1 →read by rule
“An orally bioavailable inhibitor of the serine/threonine enzyme hematopoietic progenitor kinase-1 (Hpk1; Hpk-1; mitogen-activated protein kinase kinase kinase kinase 1; MAP4K1; MEKKK1), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06727630Melanoma · China | 2 | Recruiting | Apr 30, 2025 | 40 |
| NCT05315167Hereditary Sensory and Autonomic Neuropathies · China | 2 | Recruiting | May 15, 2027 | 267 |
| NCT05159700Hereditary Sensory and Autonomic Neuropathies · United States | 1 | Active, not recruiting | Jul 17, 2024 | 39 |
How it is read
Names in the registry
- “PRJ1-3024”, 3 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.